Form 8-K - Current report:
SEC Accession No. 0001140361-25-040796
Filing Date
2025-11-06
Accepted
2025-11-06 16:31:47
Documents
16
Period of Report
2025-11-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ny20058362x2_8k.htm   iXBRL 8-K 43157
2 EXHIBIT 4.1 ny20058362x2_ex4-1.htm EX-4.1 97339
3 EXHIBIT 5.1 ny20058362x2_ex5-1.htm EX-5.1 14373
4 EXHIBIT 10.1 ny20058362x2_ex10-1.htm EX-10.1 330149
8 ny20058362x2_ex5-1logo01.jpg GRAPHIC 34391
  Complete submission text file 0001140361-25-040796.txt   755567

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA ird-20251105.xsd EX-101.SCH 3860
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE ird-20251105_lab.xml EX-101.LAB 21967
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ird-20251105_pre.xml EX-101.PRE 16042
19 EXTRACTED XBRL INSTANCE DOCUMENT ny20058362x2_8k_htm.xml XML 4216
Mailing Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27713
Business Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27713 248-681-9815
Opus Genetics, Inc. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 251458982
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)